Q
Qihan Biotech
Qihan Biotech is a Healthcare Start Up Based in Hangzhou
About Qihan Biotech
Qihan Biotech is a leading biotechnology startup based in Hangzhou, China, that specializes in the development of stem cell-derived cell therapy products. The company leverages its world-class capabilities in multiplexable gene editing, a process that allows for the simultaneous modification of multiple genes, to create innovative treatments for various diseases.
The company's primary focus is on the development of therapies for immune-privileged diseases, which are conditions that the immune system typically does not respond to. Qihan Biotech's products are designed to modify the genome of cells to make them immune-privileged, thereby enabling the body's immune system to fight off these diseases.
Qihan Biotech recently completed a pre-Series B financing round, raising over $16 million. This funding will be used to further develop and commercialize its cell therapy products. The company's business model revolves around the research, development, and sale of these innovative therapies.
One of Qihan Biotech's most promising products is QN-019a, a multi-locus gene-editing cell therapy product designed to treat CD19-positive B-Cell Lymphoma. The company recently received approval from the National Medical Products Administration (NMPA) to begin clinical trials for this product.
Qihan Biotech operates in the rapidly growing market of gene therapy and stem cell research. Its potential clients include hospitals, research institutions, and patients suffering from diseases that are currently untreatable with conventional therapies.
In summary, Qihan Biotech is a pioneering biotech startup that uses advanced gene editing techniques to develop innovative cell therapy products. The company's successful fundraising efforts and regulatory approvals indicate a promising future in the burgeoning field of gene therapy.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Hangzhou, China
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 65.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Sep 2023 | $14M | $335M | Zhejiang Industrial Fund | ↗ |
| SERIES AOther financing | Mar 2021 | $67M | $268M | Lilly Asia Ventures · Sequoia · CMB International · Matrix Partners China | — |
Growth signals
Latest recorded traffic for Qihan Biotech is 9.8K monthly website visits, up 117.8% over the last three months. Qihan Biotech's team declined 22.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Qihan Biotech in the Hangzhou ecosystem
The Qihan Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
Sequoia
ARCH Venture Partners
HongShan
Biomatics Capital Partners
NLVC
Alta Partners
Legend Star
CMB International Capital- CICMB International
Lilly Asia Ventures
Matrix Partners China- ZFZhejiang Industrial Fund
Other known investors1 additional known investor
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Qihan Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Qihan Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










